Form 7 Monthly Progress Report July 2023
Form 7 Monthly Progress Report July 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 August 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report June 2023
Form 7 Monthly Progress Report May 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 July 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting BioMark’s blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting. Vancouver, British Columbia – (June 5th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with […]
Biomark’s Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting
Biomark’s Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting Biomark Diagnostics, an early stage cancer research company based in Richmond, Canada, made a significant stride in its quest to advance cancer research by presenting at the prestigious ASCO (American Society of Clinical Oncology) 2023 Annual Meeting. The ASCO Annual Meeting is globally recognized as one […]
BIOMARK ANNOUNCES The U.S. Patent and Trademark Office Granted PATENT WITH CLAIMS COVERING ITS LUNG CANCER LIQUID BIOPSY ASSAY
The new family of patent granted by USPTO strengthens BioMark’s global intellectual property position in liquid biopsy and early cancer detection. Vancouver, British Columbia – (May 31st, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers […]
Form 7 Monthly Progress Report May 2023
Form 7 Monthly Progress Report May 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 June 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report April 2023
Form 7 Monthly Progress Report March 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 May 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Press Release – BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2023
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark’s liquid biopsy platform, to be presented. Vancouver, British Columbia – (May 3rd, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) […]
Form 7 Monthly Progress Report March 2023
Form 7 Monthly Progress Report March 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 April 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March 16th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this […]
